Subscribe to MDT Magazine News

Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients

September 8, 2010 1:36 pm | by Bio-Medicine.Org | Comments

ST. LOUIS, Sept. 8 /- Stereotaxis, Inc. (Nasdaq: STXS ) highlighted significant new additions to the body of evidence demonstrating exceptional clinical outcomes achieved with its Niobe® Magnetic Navigation System in ventricular tachycardia (VT) ablation. At the European Cardiology...


Masimo to Present at Stifel Nicolaus 2010 Healthcare Conference

September 8, 2010 1:34 pm | by Bio-Medicine.Org | Comments

IRVINE, Calif., Sept. 8 /- Masimo (Nasdaq: MASI ) today announced that its management is scheduled to present at the Stifel Nicolaus 2010 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 15, at 8:00 a.m. ET.  A live audiocast of the presentation will...


The Pancreatic Cancer Action Network and AACR to Award Nearly $3 Million in Pancreatic Cancer Research Grants

September 8, 2010 1:34 pm | by AACR | Comments

Applications are being accepted for a variety of grants totaling nearly $3 million. PHILADELPHIA — The American Association for Cancer Research in partnership with the Pancreatic Cancer Action Network is now accepting applications for the 2011 research grants program. The program is...


Medical Devices Technology Innovation Partnership (MD-TIP) Workshop, October 26, 2010

September 8, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

Innovation, Technology Transfer and Scientific Interchange: Leveraging Academic and FDA Collaborations to Resolve Unmet Public Health Needs


Class I Medical Device Recall: AngioScore Inc. - AngioSculpt EX PTCA Scoring Balloon Catheter

September 8, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

Reason for Recall: The PTCA catheters may become separated during use in which fragments of the catheter may become lodged in coronary arteries. This may result in serious injuries, including death.


Federal Register: Guidance for Industry and Food and Drug Administration Staff; Class II Special Controls Guidance Document for Certain Percutaneous Transluminal Coronary Angi...

September 8, 2010 1:30 pm | by U.S. Food & Drug Administration | Comments

The guidance was developed as a special control to support the reclassification of PTCA catheters, other than cutting/scoring PTCA catheters, from class III (premarket approval) into class II (special controls).


Federal Register: Cardiovascular Devices; Reclassification of Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters

September 8, 2010 1:30 pm | by U.S. Food & Drug Administration | Comments

The FDA is reclassifying the device type, standard PTCA catheters, from class III (premarket approval) into class II (special controls). Cutting/scoring PTCA catheters remain in class III and continue to require PMAs.


AngioSculpt "EX" PTCA Scoring Balloon Catheter by AngioScore, Inc.: Recall - Risk of Catheter Separation

September 8, 2010 1:30 pm | by U.S. Food & Drug Administration | Comments

Fragments of the catheter may become lodged in coronary arteries, resulting in serious injury or death.


Nursing home co. settles $677M lawsuit for $50M

September 8, 2010 12:45 pm | by The Associated Press | Comments

A California nursing home company has agreed to pay $50 million to settle a lawsuit that resulted in a $677 million jury award in favor of thousands of current and former patients.Orange County-based Skilled Healthcare Group Inc. announced the settlement late Tuesday. The money will go to the...

NVCA launches MedIC life sciences coalition

September 8, 2010 7:32 am | by Mass High Tech: The Journal of New England Technology | Comments

The National Venture Capital Association, its member venture capital firms and life sciences companies are teaming up to form the Medical Innovation and Competitiveness (MedIC) Coalition, which will advocate for policies and regulations that advance medical innovation in the U.S.

Elekta Among Major Sponsors of Rocks Against Cancer Fundraiser

September 8, 2010 7:32 am | by Bio-Medicine.Org | Comments

ATLANTA, Sept. 8 /- Elekta is one of the leading supporters of the Rocks Against Cancer benefit to take place September 16 at the Angel Orensanz Foundation for the Arts in New York City. Proceeds from the event will support EIF cancer programs, including Stand Up to Cancer (SU2C), an...


NEXUS Biosystems Completes Acquisition of REMP Sample Management Business From Tecan Group

September 8, 2010 7:31 am | by Bio-Medicine.Org | Comments

POWAY, Calif., Sept. 8 /- NEXUS Biosystems, Inc., a leading innovator and worldwide provider of automated sample management systems, today announced the completion of the acquisition of REMP AG of Switzerland, a wholly-owned subsidiary of the Tecan Group.   NEXUS announced on July...


Misonix Announces New Distribution Agreement for France

September 8, 2010 6:32 am | by Bio-Medicine.Org | Comments

FARMINGDALE, N.Y., Sept. 8 /- Misonix, Inc. (Nasdaq: MSON ), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has entered into a new, three year, exclusive distribution agreement with Cormedica s.a.s.  Based...


Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology

September 8, 2010 6:31 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., Sept. 7 /- GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology . Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by...


Researchers Explore Use for Head, Neck, Prostate, Breast and Lung Tumors, as Well as More Complex Blood Cancer and Mesothelioma Treatments

September 8, 2010 5:45 am | by The Associated Press | Comments

TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, today announced that 82 studies examining the use of the TomoTherapy@ treatment system to treat common, complex and rare tumors...


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.